This phase I trial is trying to understand how safe, tolerable and effective a combination of targeted therapies (blinatumomab and AMG 404) is in people with Acute Lymphoblastic Leukaemia (ALL).
This trial is treating patients with Acute Lymphoblastic Leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Commercial Sponsor
AMGEN
Summary
This is a single group assignment trial seeking to evaluate blinatumomab in combination with AMG 404 in adults with acute lymphoblastic leukaemia (ALL), and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab. All participants in this trial will receive blinatumomab (via cIV) and AMG 404 (administered as an intravenous infusion. Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment as needed.
Recruiting Hospitals Read More